翻訳と辞書 Words near each other ・ Protestant Christian Church in Mentawai ・ Protestant Christian Church of Nias ・ Protestant Church in Baden ・ Protestant Church in East Timor ・ Protestant Church in Hesse and Nassau ・ Protestant Church in Indonesia ・ Protestant Church in Sabah ・ Proteocephalidea ・ Proteocephalinae ・ Proteoceratidae ・ Proteodoxa ・ Proteogenomics ・ Proteoglycan ・ Proteoideae ・ Proteolipid protein 1 ・ Proteolix ・ Proteolysis ・ Proteome ・ Proteome Analyst ・ Proteomics ・ Proteomics (journal) ・ Proteomics Identifications Database ・ Proteomics Standards Initiative ・ Proteomyrus ・ Proteomyxa ・ Proteomyxidea ・ Proteon Therapeutics ・ Proteopathy ・ Proteopedia ・ Proteopharmacis Dictionary Lists mini英和辞書 mini和英辞書 Webster 1913 Latin-English FOLDOC Wikipedia English ウィキペディア

翻訳と辞書　辞書検索 [ 開発暫定版 ] スポンサード リンク Proteolix ： ウィキペディア英語版 Proteolix Proteolix, Inc., was a private biotechnology company with headquarters in South San Francisco, California. Proteolix focused primarily on the proteasome as a therapeutic target. Its lead product candidate, carfilzomib (PR-171), is a tetrapeptide epoxyketone. At the time of its sale (see below), the company had two earlier-stage programs, an orally-bioavailable proteasome inhibitor for oncology (PR-047), and an agent preferentially targeting the immuno form of the proteasome (PR-957), with potential utility in areas such as rheumatoid arthritis. At the time of sale, Carfilzomib's route of administration was intravenous, and the company was exploring its potential utility in multiple myeloma, Non-Hodgkin lymphoma (NHL) and other cancers. Proteolix was acquired by Onyx Pharmaceuticals in 2009 for $810 million (nominal value). Onyx renamed PR-047 to "(ONX 0912 )" and PR-957 to "(ONX 0914 )". ==External links== *(Proteolix's corporate website ) 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Proteolix」の詳細全文を読む スポンサード リンク 翻訳と辞書 : 翻訳のためのインターネットリソース Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.